Literature DB >> 20069293

Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Walter Jentzen1, Robert F Hobbs, Alexander Stahl, Jochen Knust, George Sgouros, Andreas Bockisch.   

Abstract

PURPOSE: Salivary gland impairment following high activity radioiodine therapy of differentiated thyroid cancer (DTC) is a severe side effect. Dosimetric calculations using planar gamma camera scintigraphy (GCS) with (131)I and ultrasonography (US) provided evidence that the average organ dose per administered (131)I activity (ODpA) is too low to account for observed radiation damages to the salivary glands. The objective of this work was to re-estimate the ODpA using (124)I PET(/CT) as a more reliable approach than (131)I GCS/US.
METHODS: Ten DTC patients underwent a series of six (or seven) PET scans and one PET/CT scan after administration of approximately 23 MBq (124)I-iodide. Volumes of interest (VOIs) drawn on the CT and serial PET images were used to determine the glandular volumes and the imaged (124)I activities. To enable identical VOIs to be drawn on serial PET images, each PET was co-registered with the CT image. To correct for partial volume effect and for the artificial bias in the activity concentration due to cascading gamma coincidences occurring in (124)I decay, the imaged activity was effectively corrected using isovolume recovery coefficients (RCs) based on recovery phantom measurements. A head-neck phantom, which contained (124)I-filled spheres, was manufactured to validate the isovolume recovery correction method with a realistic patient-based phantom geometry and for a range of activity concentration regimes. The mean+/-standard deviation (range) ODpA projected for (131)I was calculated using the absorbed dose fraction method.
RESULTS: The ODpAs (in Gy/GBq) for the submandibular and parotid glands were 0.32 +/- 0.13 (0.18-0.55) and 0.31 +/- 0.10 (0.13-0.46), respectively. No significant differences (p> 0.2) in the mean ODpA between (124)I PET(/CT) and (131)I GCS/US dosimetry was found. The validation experiment showed that the percentage deviations between RC-corrected and true activity concentrations were <10%.
CONCLUSION: (124)I PET(/CT) dosimetry also corroborates the low ODpAs to the salivary glands. A voxel-based calculation taking into account the nonuniform activity distributions in the glands is necessary to possibly explain the radiation-induced salivary gland damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069293      PMCID: PMC2854857          DOI: 10.1007/s00259-009-1351-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

1.  Recovery correction for quantitation in emission tomography: a feasibility study.

Authors:  L Geworski; B O Knoop; M L de Cabrejas; W H Knapp; D L Munz
Journal:  Eur J Nucl Med       Date:  2000-02

2.  REVISED AVERAGE GEOMETRIC FACTORS FOR CYLINDERS IN ISOTOPE DOSAGE. I.

Authors:  E F FOCHT; E H QUIMBY; M GERSHOWITZ
Journal:  Radiology       Date:  1965-07       Impact factor: 11.105

3.  An improved MCNP version of the NORMAN voxel phantom for dosimetry studies.

Authors:  P Ferrari; G Gualdrini
Journal:  Phys Med Biol       Date:  2005-08-31       Impact factor: 3.609

Review 4.  The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.

Authors:  Glenn Flux; Manuel Bardies; Myriam Monsieurs; Sauli Savolainen; Sven-Erik Strands; Michael Lassmann
Journal:  Z Med Phys       Date:  2006       Impact factor: 4.820

5.  Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

Authors:  K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; G Tönshoff; C Sippel; H Wolf; M Clausen; E Henze
Journal:  Nucl Med Commun       Date:  1996-08       Impact factor: 1.690

6.  Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.

Authors:  Walter Jentzen; Elke Schneider; Lutz Freudenberg; Ernst G Eising; Rainer Görges; Stefan P Müller; Wofgang Brandau; Andreas Bockisch
Journal:  Nucl Med Commun       Date:  2006-08       Impact factor: 1.690

7.  [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].

Authors:  K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; S Kalina; M Clausen; E Henze
Journal:  Nuklearmedizin       Date:  1997-04       Impact factor: 1.379

8.  Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?

Authors:  Kunihiro Nakada; Tetsuya Ishibashi; Toshiki Takei; Kenji Hirata; Katsura Shinohara; Seiichi Katoh; Sonji Zhao; Nagara Tamaki; Yasushi Noguchi; Shiro Noguchi
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

9.  124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison.

Authors:  Robert F Hobbs; Richard L Wahl; Martin A Lodge; Mehrbod S Javadi; Steve Y Cho; David T Chien; Marge E Ewertz; Caroline E Esaias; Paul W Ladenson; George Sgouros
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

10.  An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues.

Authors:  S M Jhiang; J Y Cho; K Y Ryu; B R DeYoung; P A Smanik; V R McGaughy; A H Fischer; E L Mazzaferri
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

View more
  16 in total

Review 1.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

2.  The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Authors:  Walter Jentzen; Dorothee Balschuweit; Jochen Schmitz; Lutz Freudenberg; Ernst Eising; Thomas Hilbel; Andreas Bockisch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

Review 3.  Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Authors:  George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

5.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

6.  18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients.

Authors:  Jim O'Doherty; Maite Jauregui-Osoro; Teresa Brothwood; Teresa Szyszko; Paul K Marsden; Michael J O'Doherty; Gary J R Cook; Philip J Blower; Val Lewington
Journal:  J Nucl Med       Date:  2017-04-06       Impact factor: 10.057

Review 7.  Current Status of Radiopharmaceutical Therapy.

Authors:  Sara St James; Bryan Bednarz; Stanley Benedict; Jeffrey C Buchsbaum; Yuni Dewaraja; Eric Frey; Robert Hobbs; Joseph Grudzinski; Emilie Roncali; George Sgouros; Jacek Capala; Ying Xiao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-08-14       Impact factor: 7.038

8.  Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging.

Authors:  Walter Jentzen; Marion Richter; James Nagarajah; Thorsten Dirk Poeppel; Wolfgang Brandau; Colin Dawes; Andreas Bockisch; Ina Binse
Journal:  EJNMMI Phys       Date:  2014-12-06

9.  Comparison of Imaging Characteristics of (124)I PET for Determination of Optimal Energy Window on the Siemens Inveon PET.

Authors:  A Ram Yu; Hee-Joung Kim; Sang Moo Lim; Jin Su Kim
Journal:  Biomed Res Int       Date:  2016-03-22       Impact factor: 3.411

Review 10.  Clinical Studies of Nonpharmacological Methods to Minimize Salivary Gland Damage after Radioiodine Therapy of Differentiated Thyroid Carcinoma: Systematic Review.

Authors:  Andri Christou; Evridiki Papastavrou; Anastasios Merkouris; Savvas Frangos; Panayiota Tamana; Andreas Charalambous
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.